Connect Biopharma to Participate at the Jefferies Healthcare Conference
June 02 2022 - 4:05PM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that Dr. Zheng Wei, Co-Founder & Chief Executive Officer, and
Steven Chan, Chief Financial Officer, will participate in a
fireside chat at the Jefferies Healthcare Conference on Friday,
June 10, 2022 at 10:30 am ET.
A live webcast will be available on the
Company’s Investor Relations page, accessible here:
https://investors.connectbiopharm.com/. A replay will be available
on the Company’s website following the event.
About Connect Biopharma Holdings
LimitedConnect Biopharma is a global, clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with inflammatory diseases through the development of
therapies derived from T cell-driven research. It is building a
rich pipeline of internally-designed, wholly-owned, small molecules
and antibodies using functional cellular assays with T cells to
screen and discover potent product candidates against validated
immune targets. Its lead product candidate, CBP-201, is an antibody
designed to target interleukin-4 receptor alpha (IL-4Rα) in
development for the treatment of atopic dermatitis (AD) and asthma.
The Company’s second most advanced product candidate, CBP-307, is a
modulator of a T-cell receptor known as S1P1 in development for the
treatment of UC. Clinical development has begun for its third
product candidate, CBP-174, a peripherally acting antagonist of
histamine receptor 3, for the treatment of pruritus associated with
AD.
With operations in the United States and China,
Connect Biopharma is building a rich global pipeline of molecules
and antibodies targeting several aspects of T cell biology. For
additional information, please visit www.connectbiopharm.com.
IR/PR CONTACTS: Lazar FINN PartnersDavid
Carey (IR)T: +1 (212)
867-1768david.carey@finnpartners.com
Glenn Silver (Media)T: +1 (973)
818-8198glenn.silver@finnpartners.com
Corporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Sep 2023 to Sep 2024